Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment
Nanoprodrugs, leveraging advanced nanoparticle-based delivery systems, represent a promising strategy to enhance the efficacy of immunotherapy in cancer treatment. These systems offer precise tumor targeting, controlled drug release, and the potential to modulate the immune microenvironment, address...
Saved in:
| Main Authors: | , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Elsevier
2025-06-01
|
| Series: | Materials Today Bio |
| Subjects: | |
| Online Access: | http://www.sciencedirect.com/science/article/pii/S2590006425005034 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1849434762104537088 |
|---|---|
| author | Yunfan Lin Pei Lin Xu Chen Xinyuan Zhao Li Cui |
| author_facet | Yunfan Lin Pei Lin Xu Chen Xinyuan Zhao Li Cui |
| author_sort | Yunfan Lin |
| collection | DOAJ |
| description | Nanoprodrugs, leveraging advanced nanoparticle-based delivery systems, represent a promising strategy to enhance the efficacy of immunotherapy in cancer treatment. These systems offer precise tumor targeting, controlled drug release, and the potential to modulate the immune microenvironment, addressing several limitations of conventional therapeutic approaches. This review systematically evaluates the role of nanoprodrugs in improving immunotherapy outcomes, focusing on their ability to overcome challenges such as poor bioavailability, systemic toxicity, and limited tumor specificity. We also discuss the key advantages of these systems, including their ability to co-deliver immune checkpoint inhibitors and other immunomodulatory agents, potentially enabling more synergistic and effective treatment strategies. Despite their promise, several challenges remain, including achieving precise control over drug release, integrating multiple stimulus-responsive mechanisms, addressing tumor heterogeneity, and overcoming barriers to clinical translation. The review concludes with a perspective on future directions, emphasizing the need for further optimization of nanomaterial design, improved delivery strategies, and solutions to the complexities of the tumor microenvironment to maximize the clinical impact of nanoprodrugs in cancer immunotherapy. |
| format | Article |
| id | doaj-art-af0482c467fc4b4e962fbbaa4f1d4b7c |
| institution | Kabale University |
| issn | 2590-0064 |
| language | English |
| publishDate | 2025-06-01 |
| publisher | Elsevier |
| record_format | Article |
| series | Materials Today Bio |
| spelling | doaj-art-af0482c467fc4b4e962fbbaa4f1d4b7c2025-08-20T03:26:31ZengElsevierMaterials Today Bio2590-00642025-06-013210193310.1016/j.mtbio.2025.101933Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatmentYunfan Lin0Pei Lin1Xu Chen2Xinyuan Zhao3Li Cui4Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, ChinaStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, ChinaStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, ChinaStomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China; Corresponding author.Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China; School of Dentistry, University of California, Los Angeles, Los Angeles, 90095, CA, USA; Corresponding author. Stomatological Hospital, School of Stomatology, Southern Medical University, Guangzhou, 510280, Guangdong, China.Nanoprodrugs, leveraging advanced nanoparticle-based delivery systems, represent a promising strategy to enhance the efficacy of immunotherapy in cancer treatment. These systems offer precise tumor targeting, controlled drug release, and the potential to modulate the immune microenvironment, addressing several limitations of conventional therapeutic approaches. This review systematically evaluates the role of nanoprodrugs in improving immunotherapy outcomes, focusing on their ability to overcome challenges such as poor bioavailability, systemic toxicity, and limited tumor specificity. We also discuss the key advantages of these systems, including their ability to co-deliver immune checkpoint inhibitors and other immunomodulatory agents, potentially enabling more synergistic and effective treatment strategies. Despite their promise, several challenges remain, including achieving precise control over drug release, integrating multiple stimulus-responsive mechanisms, addressing tumor heterogeneity, and overcoming barriers to clinical translation. The review concludes with a perspective on future directions, emphasizing the need for further optimization of nanomaterial design, improved delivery strategies, and solutions to the complexities of the tumor microenvironment to maximize the clinical impact of nanoprodrugs in cancer immunotherapy.http://www.sciencedirect.com/science/article/pii/S2590006425005034NanoprodrugCancer immunotherapyTumor microenvironment |
| spellingShingle | Yunfan Lin Pei Lin Xu Chen Xinyuan Zhao Li Cui Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment Materials Today Bio Nanoprodrug Cancer immunotherapy Tumor microenvironment |
| title | Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment |
| title_full | Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment |
| title_fullStr | Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment |
| title_full_unstemmed | Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment |
| title_short | Harnessing nanoprodrugs to enhance cancer immunotherapy: overcoming barriers to precision treatment |
| title_sort | harnessing nanoprodrugs to enhance cancer immunotherapy overcoming barriers to precision treatment |
| topic | Nanoprodrug Cancer immunotherapy Tumor microenvironment |
| url | http://www.sciencedirect.com/science/article/pii/S2590006425005034 |
| work_keys_str_mv | AT yunfanlin harnessingnanoprodrugstoenhancecancerimmunotherapyovercomingbarrierstoprecisiontreatment AT peilin harnessingnanoprodrugstoenhancecancerimmunotherapyovercomingbarrierstoprecisiontreatment AT xuchen harnessingnanoprodrugstoenhancecancerimmunotherapyovercomingbarrierstoprecisiontreatment AT xinyuanzhao harnessingnanoprodrugstoenhancecancerimmunotherapyovercomingbarrierstoprecisiontreatment AT licui harnessingnanoprodrugstoenhancecancerimmunotherapyovercomingbarrierstoprecisiontreatment |